Chengdu Information Technology of Chinese Academy of Sciences Co.,Ltd (SHE:300678)

Inozyme Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	480.32	476.09	501.3	432.35	260.03	286.94
Trading Asset Securities	-	-	-	50.05	-	-
Cash & Short-Term Investments	480.32	476.09	501.3	482.4	260.03	286.94
Cash Growth	18.43%	-5.03%	3.92%	85.52%	-9.38%	1.42%
Accounts Receivable	257.59	273.73	332.88	297.15	383.83	340.71
Other Receivables	17.95	14.31	19.13	21.56	25.31	27.03
Receivables	275.54	288.04	352.01	318.71	409.14	367.74
Inventory	106.22	91.53	159.11	118.85	112.1	105.73
Other Current Assets	49.14	121.81	38.05	55.26	28.09	25.34
Total Current Assets	911.22	977.47	1,050	975.23	809.36	785.75
Property, Plant & Equipment	22.14	23.21	23.3	26.18	18.85	19.07
Long-Term Investments	146.13	132.41	129.58	122.23	118.52	113.68
Other Intangible Assets	26.46	25.71	30.63	31.04	22.04	11.45
Long-Term Deferred Tax Assets	31.28	33.08	27.76	23.72	16.81	11.9
Long-Term Deferred Charges	0.84	0.91	1.31	0.63	-	-
Total Assets	1,138	1,193	1,263	1,179	985.59	941.86
Accounts Payable	102.19	168.87	186.26	150.89	156.78	118.02
Accrued Expenses	3.87	44.43	54.74	54.9	47.11	41.46
Short-Term Debt	12.49	12.51	0.6	10.01	-	32.04
Current Portion of Leases	2.24	2.42	1.95	1.67	0.76	-
Current Income Taxes Payable	29.95	0.91	4.77	9.5	6.47	2.6
Current Unearned Revenue	80.49	63.15	118.09	58.81	43.11	43.84
Other Current Liabilities	33.43	28.99	25.66	46.03	85.99	26.5
Total Current Liabilities	264.67	321.28	392.06	331.8	340.22	264.46
Long-Term Debt	0.32	0.32	0.32	0.32	0.32	0.32
Long-Term Leases	3.2	3.1	2.93	4.96	-	-
Long-Term Unearned Revenue	5.22	6.99	1.96	5.68	9.59	2.79
Long-Term Deferred Tax Liabilities	0.83	0.19	0.17	0.08	-	-
Other Long-Term Liabilities	1.19	1.14	1.02	1.63	1.32	0.94
Total Liabilities	275.43	333.02	398.47	344.48	351.45	268.51
Common Stock	296.39	296.39	296.39	197.59	188.9	180
Additional Paid-In Capital	196.02	196.02	198.36	296.5	144.31	226.74
Retained Earnings	367.39	364.2	369.44	340.86	300.56	266.44
Comprehensive Income & Other	-0.09	-0.09	-0.09	-0.09	-0.09	-0.09
Total Common Equity	859.71	856.52	864.1	834.87	633.69	673.1
Minority Interest	2.92	3.25	0.47	-0.31	0.45	0.26
Shareholders' Equity	862.64	859.78	864.57	834.56	634.14	673.35
Total Liabilities & Equity	1,138	1,193	1,263	1,179	985.59	941.86
Total Debt	18.26	18.35	5.8	16.95	1.08	32.36
Net Cash (Debt)	462.07	457.74	495.5	465.45	258.95	254.58
Net Cash Growth	15.54%	-7.62%	6.46%	79.74%	1.72%	0.78%
Net Cash Per Share	1.56	1.54	1.94	1.58	0.91	0.90
Filing Date Shares Outstanding	296.39	296.39	296.39	296.39	283.35	270
Total Common Shares Outstanding	296.39	296.39	296.39	296.39	283.35	270
Working Capital	646.56	656.19	658.41	643.43	469.14	521.29
Book Value Per Share	2.90	2.89	2.92	2.82	2.24	2.49
Tangible Book Value	833.26	830.81	833.48	803.82	611.64	661.64
Tangible Book Value Per Share	2.81	2.80	2.81	2.71	2.16	2.45
Buildings	-	25.52	25.52	25.52	25.52	25.52
Machinery	-	18.21	17.63	16.25	13.76	13.05

Updated Oct 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.